Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Articles|March 13, 2026
Where Teledermatology is Today: Expanding Access and Navigating Limits
Author(s)Tim Smith
Fact checked by: Ryan Livingston
In this feature, 3 experts discuss the expansion of telehealth and telemedicine use, including their positive and negative aspects in dermatology today.
Advertisement
Advertisement
Telemedicine use among patients has expanded dramatically in recent years, and the practice’s ability to expand access to patients regardless of location has shifted the way medicine is practiced.1
Related to this article
In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Advertisement
Advertisement